Results 21 to 30 of about 1,831 (172)

Considerations for Menstrual Suppression in Patients With Hematologic Malignancies. [PDF]

Pharmacotherapy
ABSTRACT Patients who menstruate during treatment for hematologic malignancies have a higher risk of heavy vaginal bleeding due to thrombocytopenia caused by malignancy and myelosuppressive chemotherapy. Heavy menstrual bleeding is associated with significant morbidity in this patient population, and menstrual suppression is a standard of supportive ...
Veeravalli S, Schepers A, Benitez LL, Fraga MS.   +3 more
europepmc   +2 more sources

Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis

BMC Women's Health, 2022
Background Elagolix is effective and safe for treating menorrhagia in women with uterine fibroid. However, it is reported to be associated with hypoestrogenism that can be alleviated by adding estradiol/norethindrone acetate.
Juliawati Muhammad, Yusnita Yusof, Imran Ahmad, Mohd Noor Norhayati   +3 more
doaj   +2 more sources

From Endometriosis to Encapsulation: A Case Report of Endometriosis Causing Sclerosing Encapsulating Peritonitis. [PDF]

Case Rep Obstet Gynecol
Sclerosing encapsulating peritonitis is a rare complication of endometriosis that has sparsely been described in the literature. It involves the development of a thick gray‐white fibrotic membrane, which partially or completely encases the small bowel and can spread intraperitoneally to involve surrounding organs, leading to significant morbidity and ...
Frankel L, Stearns K, Kuan-Celarier A, Childs D, Moulder J.   +4 more
europepmc   +2 more sources

A Matched Case-Control Study Examining the Association Between Exposure to Depot Medroxyprogesterone Acetate and Cerebral Meningioma Using an Active Comparator [PDF]

Current Oncology
The recent literature has reported an increased association between the use of depot medroxyprogesterone acetate (dMPA) and cerebral meningioma (CM). Prior studies have been limited in generalizability and did not use an active comparator as a control ...
Russell Griffin, Rebecca Arend
doaj   +2 more sources

Bone mineral density with elagolix plus add-back therapy in women with heavy menstrual bleeding and uterine fibroids: open-label and post-treatment results of a 60-month phase 3 trialAJOG Global Reports at a Glance [PDF]

AJOG Global Reports
Background: The gonadotropin-releasing hormone antagonist elagolix (ELA) plus hormonal add-back (+AB) therapy reduces menstrual blood loss in women with heavy menstrual bleeding (HMB) associated and uterine fibroids.
Vicki L. Schnell, MD, Liesl K. Bredeson, MD, Eric Brown, MD, Anna Chan, PharmD, James Thomas, MS, James Simon, MD, Michael C. Snabes, MD, PhD   +6 more
doaj   +2 more sources

Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids. [PDF]

Drugs, 2022
Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of ...
Syed YY.
europepmc   +2 more sources

Treatment of Endometriosis and Chronic Pelvic Pain with Letrozole and Norethindrone Acetate. [PDF]

Med J Armed Forces India, 2010
Endometriosis is encountered in 7-10% of actively menstruating women, with a suspected prevalence as high as 22% in asymptomatic women. It is an important cause of chronic pelvic pain. The aim of this study was to evaluate the efficacy and safety of letrozole in combination with norethindrone acetate and calcium in the management of endometriosis ...
Chawla S.
europepmc   +4 more sources

Dydrogesterone and Letrozole Combination for the Treatment of Endometriosis: A Mechanism-Based Therapeutic Approach. [PDF]

Obstet Gynecol Int
Endometriosis is a complex, estrogen‐dependent disease with limited effective treatments that often focus on symptom management rather than addressing the underlying pathology. Current therapies, such as progestins and GnRH agonists, have significant side effects (weight gain, mood changes, decreased bone mineral density, and menopausal symptoms) and ...
Rai SK, Kumar R, Khan MI, Kumar A.
europepmc   +2 more sources

Safety and efficacy of relugolix combination therapy in symptomatic uterine fibroids [PDF]

Facts, Views & Vision in ObGyn
Background: Relugolix-combination therapy (CT) (oestradiol 1 mg and norethindrone acetate 0.5 mg) is a new gonadotropin-releasing hormone antagonist licensed to treat heavy menstrual bleeding (HMB) associated with uterine fibroids; but little real-world ...
Maria Chiara De Angelis, Fedora Ambrosetti, Sabrina Reppuccia, Fabiola Nardelli, Brunella Zizolfi, Antonella Mercurio, Antonio Maiorana, Attilio Di Spiezio Sardo   +7 more
doaj   +2 more sources

The effects of starter feed on intestinal fungi and non-targeted metabolomics of blood in calf yaks [PDF]

BMC Microbiology
Yaks are the primary ruminant on the Qinghai-Xizang Plateau, playing a central role in the livelihoods of local farmers and herders. They serve as a vital source of food, clothing, shelter, and transportation in the region.
Hongzhuang Wang, Duojie Qingni, Qing He, Zhandui Pingcuo, Nan Jiang, Yanbin Zhu, Qiang Zhang, Guifang Liu, Guangming Sun, Yangji Cidan, Faisal Ayub Kiani, Dunzhu Luosang, Wangdui Basang   +12 more
doaj   +2 more sources